{
  "nctId": "NCT02979522",
  "briefTitle": "A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma",
  "officialTitle": "An Open-Label Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma",
  "protocolDocument": {
    "nctId": "NCT02979522",
    "filename": "Prot_002.pdf",
    "label": "Study Protocol",
    "date": "2021-06-11",
    "uploadDate": "2022-03-22T16:35",
    "size": 14999394,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02979522/document/Prot_002.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE1",
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NON_RANDOMIZED",
  "interventionModel": "SEQUENTIAL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 59,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2017-09-06",
    "completionDate": "2029-09-24",
    "primaryCompletionDate": "2020-05-05",
    "firstSubmitDate": "2016-11-11",
    "firstPostDate": "2016-12-01"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\nEach participant must meet all the following inclusion criteria to be enrolled in the study:\n\n1. Histologically confirmed CD30+ classical HL.\n2. Advanced stage, newly diagnosed HL (Stage III and Stage IV disease).\n3. Treatment-naive HL.\n4. Have performance scores of greater than or equal to (\\>=) 50 for Lansky Play-performance or Karnofsky Performance Status.\n5. Have bidimensional measurable disease as documented by radiographic technique per International Working Group (IWG) criteria.\n6. Have adequate blood counts, renal and liver function as defined in the protocol.\n\nExclusion Criteria:\n\n1. Nodular lymphocyte predominant HL.\n2. Known active cerebral/meningeal disease, including signs or symptoms of progressive multifocal leukoencephalopathy (PML) or any history of PML.\n3. Any sensory or motor peripheral neuropathy.\n4. Symptomatic neurologic disease compromising normal activities of daily living or requiring medications.\n5. Any active systemic viral, bacterial, or fungal infection requiring systemic antibiotics within 2 weeks before the first study protocol therapy.\n6. Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin or any component of AVD.\n7. Known human immunodeficiency virus positive.\n8. Known hepatitis B surface antigen positive or known or suspected active hepatitis C infection, as determined by hepatitis B DNA or hepatitis C RNA, respectively, in blood.\n9. Diagnosed or treated for another malignancy within 3 years before the first dose or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.\n10. Use of any strong or listed moderate cytochrome P450 (CYP) 3A4 inhibitors less than (\\<) 2 weeks before the first dose of protocol therapy (please refer to the Study Manual for an example list of prohibited CYP3A4 inhibitors).\n11. Any of the following cardiovascular conditions or values within 6 months before the first dose of protocol therapy:\n\n    * Shortening fraction of \\<27 percent (%) by echocardiogram or, if echocardiogram not feasible, ejection fraction of \\<50% by radionuclide angiogram (RNA or MUGA \\[multiple-gated acquisition scan\\]).\n    * New York Heart Association Class III or IV heart failure.\n    * Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure, angina, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "5 Years",
    "maximumAge": "17 Years",
    "stdAges": [
      "CHILD"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Phase 1: Recommended Dose of Brentuximab Vedotin in Combination With Doxorubicin, Vinblastine, and Dacarbazine in a Pediatric Population",
        "description": "The recommended dose was determined after considering all safety data in phase 1 and assessing for dose limiting toxicities (DLTs) which are defined as the dose range at which less than or equal to (\\<=) 1 of 6 evaluable participants experience DLT within the defined observation period (Cycle 1 + 28 days). This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.",
        "timeFrame": "From the first dose (Cycle 1) up to Day 56 (Cycle length=28 days)"
      },
      {
        "measure": "Phase 1: Percentage of Participants Who Experienced Adverse Events (AEs) From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy",
        "description": "AE means any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product. This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.",
        "timeFrame": "From first dose in Cycle 1 Day 1 until 30 days after the last dose of study drug in Cycle 6 Day 15 (up to Cycle 7 Day 15) (Cycle length=28 days)"
      },
      {
        "measure": "Phase 1: Percentage of Participants Who Experienced Serious Adverse Events (SAEs) From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy",
        "description": "AE means any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product. SAE is defined as any untoward medical occurrence that at any dose results in death, Is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, Is a congenital anomaly/birth defect, Is a medically important event.",
        "timeFrame": "From first dose in Cycle 1 Day 1 until 30 days after the last dose of study drug in Cycle 6 Day 15 (up to Cycle 7 Day 15) (Cycle length=28 days)"
      },
      {
        "measure": "Phase 2: Percentage of Participants Who Achieved a Complete Remission (CR) Per Independent Review Facility (IRF) Assessment Per International Working Group (IWG) Criteria at End of Treatment (EOT) Visit",
        "description": "CR was defined as the disappearance of all evidence of disease as assessed by IRF as per IWG Criteria. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed for all participants treated at the recommended dose in Phase 2. As prespecified in the statistical analysis plan (SAP) , data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "At end of treatment (EOT) visit 30 days after the last dose of study drug (at Month 7)"
      },
      {
        "measure": "Phase 2: Percentage of Participants Whose Disease Was Positron Emission Tomography (PET) Negative After 2 Cycles of Protocol Therapy Per IRF Assessment",
        "description": "The Deauville score according to IRF assessment of response was used to evaluate the results of PET scans. PET negative after Cycle 2 was defined as an IRF Deauville score of (1 or 2 or 3). This outcome measure was planned to be assessed for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "From first dose of study drug up to Cycle 2 Day 25 (Each Cycle length=28 days)"
      },
      {
        "measure": "Phase 2: Percentage of Participants Who Achieved a Partial Remission (PR) Per IRF Assessment Per IWG Criteria at EOT Visit",
        "description": "PR was defined as regression of measurable disease and no new sites as assessed by IRF as per IWG criteria. Percentage of participants in the response-evaluable population who achieved a partial response based on the IRF assessment at the EOT visit based on the IWG criteria are reported. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "At EOT visit 30 days after the last dose of study drug (at Month 7)"
      },
      {
        "measure": "Phase 2: Percentage of Participants Who Achieved an Overall Response Rate (ORR) Per IRF Assessment Per IWG Criteria at EOT Visit",
        "description": "Overall response rate was defined as the percentage of participants with CR or PR as assessed by IRF using IWG criteria. CR was defined as the disappearance of all evidence of disease and PR was defined as regression of measurable disease and no new diseases. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "At EOT visit 30 days after the last dose of study drug (at Month 7)"
      },
      {
        "measure": "Phase 2: Percentage of Participants Who Were Able to Complete 6 Cycles of Protocol Therapy at the Recommended Dose",
        "description": "This outcome measure was planned to be assessed for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "From first dose of study drug up to Cycle 6 (Each Cycle length=28 days)"
      }
    ],
    "secondary": [
      {
        "measure": "Phase 1: Mean Maximum Observed Serum Concentration (Cmax) of Brentuximab Vedotin Total Conjugated and Therapeutic Antibody (TAb)",
        "description": "This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.",
        "timeFrame": "Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)"
      },
      {
        "measure": "Phase 1: Mean Maximum Observed Plasma Concentration (Cmax) of Monomethyl Auristatin E (MMAE)",
        "description": "This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.",
        "timeFrame": "Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)"
      },
      {
        "measure": "Phase 1: Mean Area Under the Serum Concentration-Time Curve From Day 0 to Day 15 (AUC0-15) of Brentuximab Vedotin and TAb",
        "description": "This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.",
        "timeFrame": "Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)"
      },
      {
        "measure": "Phase 1: Mean Area Under the Plasma Concentration-Time Curve From Day 0 to Day 15 (AUC0-15) of MMAE",
        "description": "This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.",
        "timeFrame": "Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)"
      },
      {
        "measure": "Phase 1: Median Time to Reach Cmax (Tmax) of Brentuximab Vedotin and TAb in Serum",
        "description": "This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.",
        "timeFrame": "Cycle 1-6: Days 1 and 15 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)"
      },
      {
        "measure": "Phase 1: Median Time to Reach Cmax (Tmax) of MMAE in Plasma",
        "description": "This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.",
        "timeFrame": "Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)"
      },
      {
        "measure": "Phase 1: Percentage of Participants Who Achieved a CR Per IRF Assessment Per IWG Criteria at EOT Visit",
        "description": "CR was defined as the disappearance of all evidence of disease as assessed by IRF as per IWG Criteria. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed only for participants treated in Phase 1 arm.",
        "timeFrame": "At EOT visit 30 days after the last dose of study drug (at Month 7)"
      },
      {
        "measure": "Phase 1: Percentage of Participants Who Achieved a PR Per IRF Assessment Per IWG Criteria at EOT Visit",
        "description": "PR was defined as regression of measurable disease and no new diseases as per IWG Criteria based on IRF. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed only for participants treated in Phase 1 arm.",
        "timeFrame": "At EOT visit 30 days after the last dose of study drug (at Month 7)"
      },
      {
        "measure": "Phase 1: Percentage of Participants Who Achieved an ORR Per IRF Assessment Per IWG Criteria at EOT Visit",
        "description": "Overall response rate was defined as the percentage of participants with CR or PR as assessed by an IRF using IWG Revised Response Criteria. CR was defined as the disappearance of all evidence of disease and PR was defined as regression of measurable disease and no new sites. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed only for participants treated in Phase 1 arm.",
        "timeFrame": "At EOT visit 30 days after the last dose of study drug (at Month 7)"
      },
      {
        "measure": "Phase 1: Percentage of Participants Whose Disease Was PET Negative After 2 Cycles of Protocol Therapy Per IRF Assessment",
        "description": "The Deauville score according to IRF assessment of response was used to evaluate the results of PET scans. PET negative after Cycle 2 was defined as an IRF Deauville score of (1 or 2 or 3). This outcome measure was planned to be assessed only for participants treated in Phase 1 arm.",
        "timeFrame": "From first dose of study drug up to Cycle 2 (Each Cycle length=28 days)"
      },
      {
        "measure": "Phase 1: Percentage of Participants Whose Disease Was PET Positive After 6 Cycles of Protocol Therapy Per IRF Assessment",
        "description": "The Deauville score according to IRF assessment of response was used to evaluate the results of PET scans. PET positive after Cycle 6 defined as an IRF Deauville score of (4 or 5). This outcome measure was planned to be assessed only for participants treated in Phase 1 arm.",
        "timeFrame": "From first dose of study drug up to Cycle 6 (Each Cycle length=28 days)"
      },
      {
        "measure": "Phase 1: Percentage of Participants Who Were Antitherapeutic Antibody (ATA) Positive, Persistently Positive or Transiently Positive, and Neutralizing Antitherapeutic Antibody (nATA) Positive",
        "description": "ATA positive was defined as participants who have a positive ATA in any postbaseline sample. Transiently ATA positive was defined as participants who have positive ATA in 1 or 2 postbaseline samples. Persistently ATA positive was defined as participants who have positive ATA in more than 2 postbaseline timepoints. Transiently ATA positive was defined as participants who have positive ATA in 1 or 2 postbaseline samples. nATA positive was defined as participants who have at least one positive nATA in any postbaseline ATA positive sample. Here, percentage of participants who were transiently or persistently ATA positive are considered as ATA positive. This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.",
        "timeFrame": "Up to 7 months"
      },
      {
        "measure": "Phase 2: Progression-free Survival (PFS)",
        "description": "PFS per IRF:time from first dose until disease progression per IRF/death due to any cause,whichever occurred first.Participants with no objective progressive disease (PD),did not die,were still on study follow-up at time of analysis were removed from study prior to documentation of PD,PFS was censored on date of last adequate disease assessment before initiation of any non-protocol,alternative therapy.Participants who were on antitumor treatment,other than SCT/radiotherapy,censoring was at last adequate disease assessment before initiation of such alternative treatment.If participant experienced disease progression per IRF/died after initiation of antitumor treatment,other than SCT/radiotherapy,such participant was censored and not considered having PFS.Outcome measure was planned to be assessed for all participant treated at recommended dose in Phase 2.As per SAP,Phase 2 data was summarized and reported in two arms:Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Up to 24 months"
      },
      {
        "measure": "Phase 2: Event-free Survival (EFS)",
        "description": "EFS:Time from first dose until any treatment failure:PD per IRF including progression events during follow-up period,failing to complete 6 cycles of treatment due to any reason or death due to any cause,whichever occurred first.EFS per IRF were censored on last adequate disease assessment date per IRF if none of above events occur during study.Participants with antitumor treatment,other than SCT/radiotherapy as part of frontline treatment were censored at last adequate disease assessment before initiation of such alternative treatment.If a participant experienced disease progression per IRF/died after initiation of antitumor treatment,other than SCT/radiotherapy,such participant was censored,and not be considered having EFS.This outcome measure was planned to be assessed for all patients treated at recommended dose in Phase 2.As prespecified in SAP,data for Phase 2 was summarized and reported in two arms:Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Up to 24 months"
      },
      {
        "measure": "Phase 2: Overall Survival (OS)",
        "description": "Overall survival was defined as time from first dose until death. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive, including study closure. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Up to 24 months"
      },
      {
        "measure": "Phase 2: Duration of Response (DOR)",
        "description": "DOR per IRF in participants with a response (CR or PR per IRF) was defined as the time from start of the first objective tumor response (CR or PR per IRF) to the first subsequent PD or death due to any cause, whichever occurred first. For patients who did not have an objective PD, did not die and are either still on a study follow-up at the time of the analysis, or were removed from the study prior to documentation of PD, DOR has been censored on the date of last adequate disease assessment. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Up to 24 months"
      },
      {
        "measure": "Phase 2: Percentage of Participants Receiving Irradiation for HL Following Study Treatment",
        "description": "This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Up to 24 months"
      },
      {
        "measure": "Phase 2: Percentage of Participants Who Experienced AEs From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy",
        "description": "This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "From first dose in Cycle 1 Day 1 until 30 days after the last dose of study drug in Cycle 6 Day 15 (up to Cycle 7 Day 15) (Cycle length=28 days)"
      },
      {
        "measure": "Phase 2: Percentage of Participants Who Experienced SAEs From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy",
        "description": "This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "From first dose in Cycle 1 Day 1 until 30 days after the last dose of study drug in Cycle 6 Day 15 (up to Cycle 7 Day 15) (Cycle length=28 days)"
      },
      {
        "measure": "Phase 2: Percentage of Participants Who Were ATA Positive, Persistently Positive, or Transiently Positive, and nATA Positive",
        "description": "ATA positive was defined as participants who have a positive ATA in any postbaseline sample. Transiently ATA positive was defined as participants who have positive ATA in 1 or 2 postbaseline samples. Persistently ATA positive was defined as participants who have positive ATA in more than 2 postbaseline timepoints. Transiently ATA positive was defined as participants who have positive ATA in 1 or 2 postbaseline samples. nATA positive was defined as participants who have at least one positive nATA in any postbaseline ATA positive sample. Here, percentage of participants who were transiently or persistently ATA positive are considered as ATA positive. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "From first dose until 30 days after the last dose of study drug (up to 7 months)"
      },
      {
        "measure": "Phase 2: Mean Serum Cmax of Brentuximab Vedotin and TAb",
        "description": "This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)"
      },
      {
        "measure": "Phase 2: Mean Plasma Cmax of MMAE",
        "description": "This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)"
      },
      {
        "measure": "Phase 2: Mean Serum AUC0-15d of Brentuximab Vedotin and TAb",
        "description": "This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)"
      },
      {
        "measure": "Phase 2: Mean Plasma AUC0-15 of MMAE",
        "description": "This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)"
      },
      {
        "measure": "Phase 2: Median Tmax of Brentuximab Vedotin and TAb in Serum",
        "description": "This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)"
      },
      {
        "measure": "Phase 2: Median Tmax of MMAE in Plasma",
        "description": "This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)"
      },
      {
        "measure": "Phase 2: Percentage of Participants Who Experienced Peripheral Neuropathy, Regardless of Seriousness, From the First Dose of Protocol Therapy",
        "description": "Peripheral Neuropathy (PN) was defined by the peripheral neuropathy standardized MedDRA query (SMQ) broad search. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Up to 24 months"
      },
      {
        "measure": "Phase 2: Time to Onset and Resolution for All Peripheral Neuropathy Events",
        "description": "Time to onset of first event was defined as time from first dose of study drug to onset of first treatment-emergent PN event. Time to resolution was calculated as the time from onset date to the date of resolution PN (SMQ) event. Participants with multiple resolved events were counted once at the longest time to resolution. Resolution was defined as an event outcome of resolved or resolved with sequelae. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Up to 24 months"
      },
      {
        "measure": "Phase 2: Immune Reconstitution-Change From Baseline Immunoglobulin G Levels at End of Treatment (EOT)",
        "description": "This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Baseline and End of Treatment (Month 7)"
      },
      {
        "measure": "Phase 1: Percentage of Participants With Low and High ATA Titer Values",
        "description": "High ATA titer was defined as participants who have at least one postbaseline ATA titer less than (\\>) 25. Low ATA titer was defined as participants whose postbaseline ATA titer are all less than or equal to (\\<=) 25. This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.",
        "timeFrame": "Up to 6 months"
      },
      {
        "measure": "Phase 2: Percentage of Participants With Low and High ATA Titer Values",
        "description": "High ATA titer was defined as participants who have at least one postbaseline ATA titer \\>25. Low ATA titer was defined as participants whose postbaseline ATA titer are all \\<=25. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Up to 6 months"
      },
      {
        "measure": "Phase 1: Mean Cmax of Brentuximab Vedotin in ATA Positive and ATA Negative Participants",
        "description": "This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.",
        "timeFrame": "Cycle 1 and 3: Days 1 and 15 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)"
      },
      {
        "measure": "Phase 1: Mean AUC 0-15d of Brentuximab Vedotin in ATA Positive and ATA Negative Participants",
        "description": "This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.",
        "timeFrame": "Cycle 1 and 3: Days 1 and 15 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)"
      },
      {
        "measure": "Phase 1: Percentage of Participants Achieving CR Per IRF Assessment Per IWG Criteria in ATA Positive and ATA Negative Participants",
        "description": "CR was defined as the disappearance of all evidence of disease as assessed by IRF as per IWG Criteria. The data is reported per ATA status as categories. This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.",
        "timeFrame": "Up to 24 months"
      },
      {
        "measure": "Phase 1: Number of ATA Positive and ATA Negative Participants With AEs and SAEs",
        "description": "This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.",
        "timeFrame": "Up to 24 months"
      },
      {
        "measure": "Phase 2: Mean Cmax of Brentuximab Vedotin in ATA Positive and ATA Negative Participants",
        "description": "This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Cycle 1-3: Days 1 and 15 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)"
      },
      {
        "measure": "Phase 2: Mean AUC 0-15 of Brentuximab Vedotin in ATA Positive and ATA Negative Participants",
        "description": "This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Cycle 1-3: Days 1 and 15 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)"
      },
      {
        "measure": "Phase 2: Percentage of Participants Achieving CR Per IRF Assessment Per IWG Criteria in ATA Positive and ATA Negative Participants",
        "description": "CR is defined as the disappearance of all evidence of disease as assessed by IRF as per IWG Criteria. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Up to 24 months"
      },
      {
        "measure": "Phase 2: Number of ATA Positive and ATA Negative Participants With AEs and SAEs",
        "description": "This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Up to 24 months"
      },
      {
        "measure": "Phase 2: Immune Reconstitution-Change From Baseline in Immunoglobulin M at the End of Treatment (EOT)",
        "description": "This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Baseline, EOT [Month 7]"
      },
      {
        "measure": "Phase 2: Immune Reconstitution-Change From Baseline in Immunoglobulin A at EOT",
        "description": "This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Baseline, EOT [Month 7]"
      },
      {
        "measure": "Phase 2: Immune Reconstitution-Change From Baseline in Tetanus at EOT",
        "description": "This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Baseline, EOT [Month 7]"
      },
      {
        "measure": "Phase 2: Immune Reconstitution-Change From Baseline in Haemophilus Influenzae B Antibody, IgG at EOT",
        "description": "This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Baseline, EOT [Month 7]"
      },
      {
        "measure": "Phase 2: Immune Reconstitution-Change From Baseline Poliovirus Antibodies Ratio at EOT",
        "description": "This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Baseline, EOT [Month 7]"
      },
      {
        "measure": "Phase 2: Immune Reconstitution-Change From Baseline Total Immunoglobulin at EOT",
        "description": "This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Baseline, EOT [Month 7]"
      },
      {
        "measure": "Phase 2: Immune Reconstitution-Change From Baseline in Peripheral Blood CD34+A at EOT",
        "description": "This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Baseline, EOT [Month 7]"
      },
      {
        "measure": "Phase 2: Immune Reconstitution-Change From Baseline in Total Lymphocyte Count at EOT",
        "description": "This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Baseline, EOT [Month 7]"
      },
      {
        "measure": "Phase 2: Immune Reconstitution-Change From Baseline in the Percentage of CD4+ (CD4+CD45RA-CD197- and CD4+CD45RA+CD197+) Subset of Cells at EOT",
        "description": "This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Baseline, EOT [Month 7]"
      },
      {
        "measure": "Phase 2: Immune Reconstitution-Change From Baseline in the Percentage of CD8+ (CD8+CD45RA-CD197- and CD8+CD45RA-CD197+) Subset of Cells at EOT",
        "description": "This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.",
        "timeFrame": "Baseline, EOT [Month 7]"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 8,
      "secondaryCount": 49,
      "otherCount": 0,
      "totalCount": 57
    },
    "studyDesign": {
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SEQUENTIAL"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:30:52.142Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}